Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients with Advanced Breast and Gastrointestinal Tumors
Conditions
Gastrointestinal Tumors | Metastatic Breast Cancer
What is the purpose of this trial?
This is a pilot study of sorafenib combined with capecitabine in subjects with histologically confirmed unresectable or metastatic breast or GI tumors. Using a 7-days-on/7-days-off schedule, our study will evaluate the safety and feasibility of fixed dose capecitabine in combination with sorafenib given at the ongoing phase III study dose of 600 mg daily. This alternate dosing schedule may mitigate the toxic side effects associated with capecitabine while allowing for equal or superior efficacy.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Bayer Pharmaceuticals
Yale Cancer Center - Dates:
- July 2012
- Last Updated:
- Study HIC#:
- 1112009424
Clinicaltrials.gov ID: Yale0051494
